Supernus Pharmaceuticals Files 8-K

TL;DR

SUPN filed an 8-K with updated financials and exhibits on Oct 17.

AI Summary

On October 17, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulation FD disclosure. No specific material events or financial figures beyond the filing date and company information were detailed in the provided text.

Why It Matters

This filing indicates Supernus Pharmaceuticals is providing updated financial statements and exhibits, which are crucial for investors to assess the company's financial health and operational status.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate adverse events.

Key Players & Entities

• Supernus Pharmaceuticals, Inc. (company) — Registrant
• October 17, 2024 (date) — Filing Date
• Delaware (jurisdiction) — State of Incorporation
• Rockville, MD (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share SUPN The Nasdaq Sto

Filing Documents

• supn-20241017.htm (8-K) — 29KB
• ex-991xsupnspnx820phase2ar.htm (EX-99.1) — 20KB
• image_0.jpg (GRAPHIC) — 5KB
• 0001356576-24-000058.txt ( ) — 184KB
• supn-20241017.xsd (EX-101.SCH) — 2KB
• supn-20241017_lab.xml (EX-101.LAB) — 21KB
• supn-20241017_pre.xml (EX-101.PRE) — 12KB
• supn-20241017_htm.xml (XML) — 3KB

01 Regulation FD

Item 7.01 Regulation FD On October 17 2024, Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") issued a press release announcing data from its exploratory open-label Phase 2a clinical study of SPN-820 in adults with major depressive disorder. The Company will host a webcast and conference call at 4:30 p.m. Eastern Time on Thursday, October 17, 2024, to review the data. A live webcast with presentation slides will be available at www.supernus.com . The webcast and presentation slides will be archived on the Company's website for 60 days following the live call. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information in this Item 7.01 (including Exhibit 99.1) is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date of this report, except as shall be expressly set forth by specific reference in such filing. This Current Report on Form 8-K contains "forward-looking statements" that do not convey historical information, but relate to predicted or potential future events, such as statements of our plans, strategies and intentions. These statements can often be identified by the use of forward-looking terminology such as "believe," "expect," "intend," "may," "will," "should," or "anticipate" or similar terminology. All statements other than statements of historical facts included in this Current Report on Form 8-K are forward-looking statements. All forward-looking statements speak only as of the date of this Current Report on Form 8-K. Except for Supernus' ongoing obligations to disclose material information under the federal securities laws, Supernus undertakes no obligation to update or revise any forward-looking state

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 — Press Release Dated October 17, 2024 furnished as an Exhibit pursuant to Item 7.01 hereof. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SUPERNUS PHARMACEUTICALS, INC. DATED: October 17, 2024 By: /s/ Timothy C. Dec Timothy C. Dec Senior Vice President and Chief Financial Officer 3